Multicenter, rAndomized, Double-blind, Placebo-conTrolled, 52-week stUdy to demonstRatE the Efficacy, Safety and Tolerability of Secukinumab Injections With 2 mL Auto-injectors (300 mg) in Adult Subjects With Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms MATURE
- Sponsors Novartis Pharmaceuticals
- 10 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2019 Planned End Date changed from 22 Jun 2020 to 4 Sep 2020.
- 16 Jul 2019 Planned primary completion date changed from 26 Sep 2019 to 21 Nov 2019.